Kinnov Therapeutics

Kinnov Therapeutics

First-in-class therapy for a worldwide market

Menu

  • Company
  • Alcohol addiction
  • R&D / Pipeline
  • Product KT-110
  • Partners / Investors
  • Business strategy
  • News
  • Contact us

Kinnov Therapeutics (KT) is in the 2nd round of fund raising of 1.5 M Euros, after receiving 500,000 Euros. Alcoholic addiction represents a market of 140 millions patients. Read the full article in Republique du Centre – 2016/09/01 (French)

Kinnov Therapeutics in La Republique du Centre
kinnov September 2, 2016September 2, 2016 news
  • ← Kinnov Therapeutics in “Journal du Dimanche”
  • Emmanuel de RIVOIRE appointed General Manager of KT →

Co-funded by the horizon 2020 programme of the European Union

About us

Kinnov Therapeutics is dedicated to the R&D of innovative therapies against addiction. Supported by experienced scientists in the drug discovery and development, we have identified the key receptors of addiction. KT-110, our first-in-class lead composition, has been tested in phase 2 clinical trial for alcohol addiction.

Contact Us

Kinnov-Therapeutics

3, allée du titane
45100 Orléans, France


View Larger Map

Pages

  • Addictions: a major Public Health threat
  • Alcohol addiction
  • Business strategy
  • Company
  • Contact us
  • Home
  • Partners / Investors
  • Preclinical trials
  • Product KT-110
  • R&D / Pipeline

Copyright 2020 - Kinnov Therapeutics